Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 2
1981 2
1990 1
2019 1
2020 3
2021 3
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma.
Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D, Akatani N, Yamase T, Kunita Y, Watanabe S, Hiromasa T, Mori H, Hirata K, Watanabe S, Higuchi T, Tomonaga H, Kinuya S. Inaki A, et al. Among authors: kunita y. Ann Nucl Med. 2022 Mar;36(3):267-278. doi: 10.1007/s12149-021-01699-0. Epub 2021 Dec 6. Ann Nucl Med. 2022. PMID: 34870794 Free PMC article. Clinical Trial.
Role of bronchial hyperresponsiveness in patients with obstructive sleep apnea with asthma-like symptoms.
Sano A, Kozuka T, Watatani N, Kunita Y, Kawabata Y, Gose K, Shirahase K, Yoshikawa K, Yamazaki R, Nishikawa Y, Omori T, Nishiyama O, Iwanaga T, Sano H, Haraguchi R, Tohda Y, Matsumoto H. Sano A, et al. Among authors: kunita y. Allergol Int. 2023 Nov 9:S1323-8930(23)00110-7. doi: 10.1016/j.alit.2023.10.006. Online ahead of print. Allergol Int. 2023. PMID: 37951731 Free article.
Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma.
Wakabayashi H, Kayano D, Inaki A, Araki R, Kuroda R, Akatani N, Yamase T, Watanabe S, Hiromasa T, Kunita Y, Mori H, Saito S, Ikawa Y, Fujiki T, Kinuya S. Wakabayashi H, et al. Among authors: kunita y. Diagnostics (Basel). 2020 Sep 2;10(9):663. doi: 10.3390/diagnostics10090663. Diagnostics (Basel). 2020. PMID: 32887257 Free PMC article.
High-dose 131I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience.
Wakabayashi H, Kayano D, Inaki A, Araki R, Kuroda R, Ikawa Y, Fujiki T, Akatani N, Yamase T, Watanabe S, Hiromasa T, Kunita Y, Mori H, Saito S, Nishimura R, Wada T, Kinuya S. Wakabayashi H, et al. Among authors: kunita y. Ann Nucl Med. 2020 Nov;34(11):840-846. doi: 10.1007/s12149-020-01514-2. Epub 2020 Aug 29. Ann Nucl Med. 2020. PMID: 32862362
Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan.
Akatani N, Wakabayashi H, Kayano D, Inaki A, Takata A, Hiromasa T, Yamase T, Kunita Y, Watanabe S, Mori H, Saito S, Nakajima K, Kinuya S. Akatani N, et al. Among authors: kunita y. Endocr J. 2023 Mar 28;70(3):315-322. doi: 10.1507/endocrj.EJ22-0463. Epub 2022 Dec 24. Endocr J. 2023. PMID: 36567077 Free article.
16 results